Safety and efficacy profile of Spiriva® Respimat® in the treatment of COPD
TIOSPIR™ (Tiotropium Safety and Performance in Respimat), with over 17,000 COPD patients included, was one of the largest international COPD trials ever conducted, confirmed the comparable mortality and exacerbation efficacy profile of Spiriva® Respimat® 5mcg and Spiriva® HandiHaler® 18mug.(1) (Source: Pharmacy Europe)
Source: Pharmacy Europe - September 12, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Respiratory Latest News Source Type: news
Conflicting Data on Spiriva Safety (CME/CE)
BARCELONA (MedPage Today) -- Real-world data indicating excess mortality with the mist version of tiotropium (Spiriva) was countered by further details from the TIOSPIR trial indicating no difference versus the dry powder version, which many here declared the winner in the data duel. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 11, 2013 Category: Cardiology Source Type: news
Study Reassures on Safety of Inhaled TiotropiumStudy Reassures on Safety of Inhaled Tiotropium
A major study on the safety of Boehringer Ingelheim's mist inhaler Spiriva (tiotropium) for chronic lung disease has found it does not increase the risk of early death, in contrast to an earlier analysis published two years ago. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 9, 2013 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
Large International Study of COPD Drug Finds Two Types of Inhalers Equally Safe and Effective - 9/9/13
An international study led by a Johns Hopkins pulmonary expert finds that the drug tiotropium, marketed as the Spiriva brand, can be delivered safely and effectively to people with chronic obstructive pulmonary disease - COPD - in both mist and traditional dry powder inhalers. (Source: Johns Hopkins Medicine News)
Source: Johns Hopkins Medicine News - September 9, 2013 Category: Research Source Type: news
Large international study of COPD drug finds 2 types of inhalers equally safe and effective
(Johns Hopkins Medicine) An international study led by a Johns Hopkins pulmonary expert finds that the drug tiotropium (marketed as the Spiriva brand), can be delivered safely and effectively to people with chronic obstructive pulmonary disease in both "mist" and traditional "dry powder" inhalers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2013 Category: Global & Universal Source Type: news
Spiriva Mist Equals Powder for Mortality
BARCELONA (MedPage Today) -- The mist version of tiotropium (Spiriva) was as safe as the dry powder formulation in terms of mortality and cardiovascular events in chronic obstructive pulmonary disease, the TIOSPIR trial showed. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 31, 2013 Category: Primary Care Source Type: news
Eklira® Genuair® Provides Significant Improvements In COPD Symptoms Vs Placebo In A 6-Week Study
New Phase IIIb data published in the journal COPD demonstrates comparable efficacy for twice-daily Eklira® Genuair® (aclidinium) vs tiotropium following the 6-week study1. The data show significant improvements in 24-hour bronchodilation for aclidinium vs placebo from day 1 of treatment1. Significant improvements in bronchodilation vs tiotropium were found on day 1 with comparable bronchodilation vs tiotropium at week 61... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 12, 2013 Category: Consumer Health News Tags: COPD Source Type: news
Tiotropium in symptomatic asthma patients
Tiotropium delivered by the Respimat Soft Mist Inhaler increases time to first severe exacerbation (p=0.03) and first episode of asthma worsening (p (Source: Pharmacy Europe)
Source: Pharmacy Europe - May 21, 2013 Category: Drugs & Pharmacology Source Type: news
Novartis once-daily QVA149 in reducing exacerbations in COPD
Results from the 64-week SPARK study published today in Lancet Respiratory Medicine showed that investigational once-daily dual bronchodilator QVA149 (indacaterol maleate 110mcg/glycopyrronium 50mcg) was more effective at reducing all chronic obstructive pulmonary disease (COPD) exacerbations compared to glycopyrronium 50mcg and open-label (OL) tiotropium 18 mcg[1] a treatment with established efficacy in preventing exacerbations.[2–5] This is the first study to evaluate the effect on exacerbations of dual bronchodilation with a fixed-dose combination of a long-acting beta2-agonist (LABA) and a long-acting muscarinic ant...
Source: Pharmacy Europe - April 24, 2013 Category: Drugs & Pharmacology Source Type: news
More Evidence Tiotropium Soft Mist Inhaler Raises Risk of DeathMore Evidence Tiotropium Soft Mist Inhaler Raises Risk of Death
Dutch researchers found a nearly 30% increased risk of death in patients using tiotropium Respimat soft mist inhaler compared with those using tiotropium dry powder inhaler. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 4, 2013 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
Phase III Results: Tiotropium Respimat® Is Effective In Symptomatic Asthma Patients Irrespective Of Their Allergic Status
New Phase III data presented for the first time at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Tiotropium delivered once daily via Respimat™ significantly improved lung function and reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICS[1]/LABA[2], irrespective of their allergic status... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 26, 2013 Category: Consumer Health News Tags: Respiratory / Asthma Source Type: news
Possible alternate therapy for adults with poorly controlled asthma
Tiotropium bromide effective when added to low-dose inhaled corticosteroids (Source: BWH News)
Source: BWH News - September 19, 2010 Category: Hospital Management Source Type: news
